Advertisement

Reactions Weekly

, Volume 1729, Issue 1, pp 32–32 | Cite as

Antineoplastics

Sinusoidal obstruction syndrome/veno-occlusive disease: 4 case reports
Case report
  • 54 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series, 4 patients (3 men and 1 woman) aged 56−68 years were described, who developed sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) during treatment with oxaliplatin, rituximab, dexamethasone and cytarabine for lymphoma [routes and dosages not stated].

Case 1: The 56-year-old man, who had diffuse large B-cell lymphoma, received 8 cycles of R-CHOP therapy consisting of rituximab, cyclophosphamide, vincristine [Oncovin] and doxorubicin [hydroxy doxorubicin] with partial response. He then received 3 cycles of salvage chemotherapy with R-DHAO regimen, which consisted of rituximab, dexamethasone, cytarabine and oxaliplatin, and underwent an autologous transplantation following conditioning regimen. He presented 7 days after transplant with anasarca...

Reference

  1. Bernichon E, et al. Sinusoidal obstruction syndrome/veno-occlusive disease complication in lymphoma patients treated with oxaliplatin-based regimen: A case series report. Current Research in Translational Medicine 66: 107-110, No. 4, Nov 2018. Available from: URL: http://doi.org/10.1016/j.retram.2018.01.004 - FranceCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations